AAPL343.93+4.43 (+1.30%) ▲|ABBV284.67-4.41 (-1.53%) ▼|ABT100.56-1.89 (-1.84%) ▼|ACN240.28+1.16 (+0.49%) ▲|ADBE255.06-1.67 (-0.65%) ▼|AMAT408.94+3.96 (+0.98%) ▲|AMD552.72+17.98 (+3.36%) ▲|AMGN438.34-0.60 (-0.14%) ▼|AMT177.63-5.93 (-3.23%) ▼|AMZN262.37-0.26 (-0.10%) ▼|AVGO337.80+3.43 (+1.03%) ▲|AXP323.64+5.30 (+1.66%) ▲|BA192.31+1.84 (+0.97%) ▲|BAC50.80+0.16 (+0.32%) ▲|BKNG158.38-5.54 (-3.38%) ▼|BLK1,149.10+20.42 (+1.81%) ▲|BMY61.16-0.53 (-0.85%) ▼|BNY145.85+1.60 (+1.11%) ▲|BRK-B541.16+1.34 (+0.25%) ▲|C123.84+1.33 (+1.08%) ▲|CAT740.16+14.92 (+2.06%) ▲|CL93.42-1.13 (-1.19%) ▼|CMCSA22.08-0.28 (-1.25%) ▼|COF206.49+4.93 (+2.44%) ▲|COP145.70-0.25 (-0.17%) ▼|COST998.31+3.70 (+0.37%) ▲|CRM241.72-0.71 (-0.29%) ▼|CSCO107.26+0.55 (+0.52%) ▲|CVS93.45-1.30 (-1.37%) ▼|CVX226.76+1.05 (+0.46%) ▲|DE636.56+4.36 (+0.69%) ▲|DHR234.02+9.78 (+4.36%) ▲|DIS111.82+0.15 (+0.13%) ▲|DUK120.69-0.64 (-0.53%) ▼|EMR163.13+2.67 (+1.66%) ▲|FDX298.18-0.58 (-0.19%) ▼|GD344.91+0.47 (+0.14%) ▲|GE295.84-4.04 (-1.35%) ▼|GEV926.39+36.06 (+4.05%) ▲|GILD153.57-2.94 (-1.88%) ▼|GM76.10-0.99 (-1.28%) ▼|GOOG330.95-5.45 (-1.62%) ▼|GOOGL334.76-5.52 (-1.62%) ▼|GS904.50+19.69 (+2.23%) ▲|HD314.08-1.03 (-0.33%) ▼|HON214.73+1.41 (+0.66%) ▲|IBM251.06+9.14 (+3.78%) ▲|INTC92.96+1.27 (+1.39%) ▲|INTU335.61+0.32 (+0.10%) ▲|ISRG428.12-9.88 (-2.26%) ▼|JNJ257.65-1.71 (-0.66%) ▼|JPM335.13-0.13 (-0.04%) ▼|KO92.68-0.82 (-0.87%) ▼|LIN500.57-1.32 (-0.26%) ▼|LLY1,272.20-11.46 (-0.89%) ▼|LMT551.97+3.26 (+0.59%) ▲|LOW196.55-0.73 (-0.37%) ▼|LRCX260.81-2.64 (-1.00%) ▼|MA622.50+2.08 (+0.33%) ▲|MCD246.22-0.30 (-0.12%) ▼|MDLZ62.74-1.25 (-1.95%) ▼|MDT93.03-1.60 (-1.69%) ▼|META697.52+3.27 (+0.47%) ▲|MMM174.69+3.32 (+1.94%) ▲|MO73.83-0.81 (-1.09%) ▼|MRK149.89+1.59 (+1.07%) ▲|MS187.11+6.71 (+3.72%) ▲|MSFT532.95+1.08 (+0.20%) ▲|MU913.67+17.60 (+1.96%) ▲|NEE78.25-0.61 (-0.77%) ▼|NFLX65.04-3.65 (-5.31%) ▼|NKE37.53-0.35 (-0.92%) ▼|NOW153.14+3.60 (+2.41%) ▲|NVDA221.97+5.50 (+2.54%) ▲|ORCL129.10-2.04 (-1.56%) ▼|PEP134.70+0.68 (+0.51%) ▲|PFE29.86-0.25 (-0.83%) ▼|PG156.89-2.43 (-1.53%) ▼|PLTR201.72+9.12 (+4.74%) ▲|PM197.47-2.43 (-1.22%) ▼|QCOM177.96+2.25 (+1.28%) ▲|RTX191.60-1.74 (-0.90%) ▼|SBUX99.08-0.29 (-0.29%) ▼|SCHW91.64+0.75 (+0.83%) ▲|SO90.39-0.32 (-0.35%) ▼|SPG205.55-1.44 (-0.70%) ▼|T21.91-1.51 (-6.45%) ▼|TMO694.29+6.92 (+1.01%) ▲|TMUS153.75-4.00 (-2.54%) ▼|TSLA386.47+12.76 (+3.41%) ▲|TXN284.65+6.87 (+2.47%) ▲|UBER67.62-1.32 (-1.91%) ▼|UNH417.00-2.26 (-0.54%) ▼|UNP287.87+0.26 (+0.09%) ▲|UPS99.57+1.05 (+1.07%) ▲|USB59.05-0.04 (-0.07%) ▼|V407.85+1.28 (+0.31%) ▲|VZ43.56-0.98 (-2.20%) ▼|WFC82.42+0.22 (+0.27%) ▲|WMT117.80-0.05 (-0.04%) ▼|XOM178.09+0.23 (+0.13%) ▲|AAPL343.93+4.43 (+1.30%) ▲|ABBV284.67-4.41 (-1.53%) ▼|ABT100.56-1.89 (-1.84%) ▼|ACN240.28+1.16 (+0.49%) ▲|ADBE255.06-1.67 (-0.65%) ▼|AMAT408.94+3.96 (+0.98%) ▲|AMD552.72+17.98 (+3.36%) ▲|AMGN438.34-0.60 (-0.14%) ▼|AMT177.63-5.93 (-3.23%) ▼|AMZN262.37-0.26 (-0.10%) ▼|AVGO337.80+3.43 (+1.03%) ▲|AXP323.64+5.30 (+1.66%) ▲|BA192.31+1.84 (+0.97%) ▲|BAC50.80+0.16 (+0.32%) ▲|BKNG158.38-5.54 (-3.38%) ▼|BLK1,149.10+20.42 (+1.81%) ▲|BMY61.16-0.53 (-0.85%) ▼|BNY145.85+1.60 (+1.11%) ▲|BRK-B541.16+1.34 (+0.25%) ▲|C123.84+1.33 (+1.08%) ▲|CAT740.16+14.92 (+2.06%) ▲|CL93.42-1.13 (-1.19%) ▼|CMCSA22.08-0.28 (-1.25%) ▼|COF206.49+4.93 (+2.44%) ▲|COP145.70-0.25 (-0.17%) ▼|COST998.31+3.70 (+0.37%) ▲|CRM241.72-0.71 (-0.29%) ▼|CSCO107.26+0.55 (+0.52%) ▲|CVS93.45-1.30 (-1.37%) ▼|CVX226.76+1.05 (+0.46%) ▲|DE636.56+4.36 (+0.69%) ▲|DHR234.02+9.78 (+4.36%) ▲|DIS111.82+0.15 (+0.13%) ▲|DUK120.69-0.64 (-0.53%) ▼|EMR163.13+2.67 (+1.66%) ▲|FDX298.18-0.58 (-0.19%) ▼|GD344.91+0.47 (+0.14%) ▲|GE295.84-4.04 (-1.35%) ▼|GEV926.39+36.06 (+4.05%) ▲|GILD153.57-2.94 (-1.88%) ▼|GM76.10-0.99 (-1.28%) ▼|GOOG330.95-5.45 (-1.62%) ▼|GOOGL334.76-5.52 (-1.62%) ▼|GS904.50+19.69 (+2.23%) ▲|HD314.08-1.03 (-0.33%) ▼|HON214.73+1.41 (+0.66%) ▲|IBM251.06+9.14 (+3.78%) ▲|INTC92.96+1.27 (+1.39%) ▲|INTU335.61+0.32 (+0.10%) ▲|ISRG428.12-9.88 (-2.26%) ▼|JNJ257.65-1.71 (-0.66%) ▼|JPM335.13-0.13 (-0.04%) ▼|KO92.68-0.82 (-0.87%) ▼|LIN500.57-1.32 (-0.26%) ▼|LLY1,272.20-11.46 (-0.89%) ▼|LMT551.97+3.26 (+0.59%) ▲|LOW196.55-0.73 (-0.37%) ▼|LRCX260.81-2.64 (-1.00%) ▼|MA622.50+2.08 (+0.33%) ▲|MCD246.22-0.30 (-0.12%) ▼|MDLZ62.74-1.25 (-1.95%) ▼|MDT93.03-1.60 (-1.69%) ▼|META697.52+3.27 (+0.47%) ▲|MMM174.69+3.32 (+1.94%) ▲|MO73.83-0.81 (-1.09%) ▼|MRK149.89+1.59 (+1.07%) ▲|MS187.11+6.71 (+3.72%) ▲|MSFT532.95+1.08 (+0.20%) ▲|MU913.67+17.60 (+1.96%) ▲|NEE78.25-0.61 (-0.77%) ▼|NFLX65.04-3.65 (-5.31%) ▼|NKE37.53-0.35 (-0.92%) ▼|NOW153.14+3.60 (+2.41%) ▲|NVDA221.97+5.50 (+2.54%) ▲|ORCL129.10-2.04 (-1.56%) ▼|PEP134.70+0.68 (+0.51%) ▲|PFE29.86-0.25 (-0.83%) ▼|PG156.89-2.43 (-1.53%) ▼|PLTR201.72+9.12 (+4.74%) ▲|PM197.47-2.43 (-1.22%) ▼|QCOM177.96+2.25 (+1.28%) ▲|RTX191.60-1.74 (-0.90%) ▼|SBUX99.08-0.29 (-0.29%) ▼|SCHW91.64+0.75 (+0.83%) ▲|SO90.39-0.32 (-0.35%) ▼|SPG205.55-1.44 (-0.70%) ▼|T21.91-1.51 (-6.45%) ▼|TMO694.29+6.92 (+1.01%) ▲|TMUS153.75-4.00 (-2.54%) ▼|TSLA386.47+12.76 (+3.41%) ▲|TXN284.65+6.87 (+2.47%) ▲|UBER67.62-1.32 (-1.91%) ▼|UNH417.00-2.26 (-0.54%) ▼|UNP287.87+0.26 (+0.09%) ▲|UPS99.57+1.05 (+1.07%) ▲|USB59.05-0.04 (-0.07%) ▼|V407.85+1.28 (+0.31%) ▲|VZ43.56-0.98 (-2.20%) ▼|WFC82.42+0.22 (+0.27%) ▲|WMT117.80-0.05 (-0.04%) ▼|XOM178.09+0.23 (+0.13%) ▲|
17.3 C
New York
Wednesday, October 21, 2026

Tag: infusion

newsFORsourcecompanycontentinformation1releasesmarket

Par Health Issues Voluntary Nationwide Recall of Two Lots of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) Due to the Presence...

ROCHESTER, Mich., Oct. 8, 2026 /PRNewswire/ -- Par Health is voluntarily recalling two lots of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection,...

Drug Delivery Devices Market to Reach US$ 698.2 Bn by 2031, Growing at 7.4% CAGR as Smart and Wearable Devices Expand: New Report by...

SHERIDAN, Wyo., Oct. 6, 2026 /PRNewswire/ -- The global drug delivery devices market is projected to grow from USD 488.6 billion in 2026 to USD...

Drug Delivery Devices Market to Reach US$ 698.2 Bn by 2031, Growing at 7.4% CAGR as Smart and Wearable Devices Expand: New Report by...

SHERIDAN, Wyo., Oct. 6, 2026 /PRNewswire/ -- The global drug delivery devices market is projected to grow from USD 488.6 billion in 2026 to USD...

LUX Infusion Strengthens Northeast Presence with Acquisition of Two Ambulatory Infusion Centers

With South Jersey Pediatric and Adult Infusion Center and Northeast Infusion Therapy joining its network, LUX Infusion expands its AIC footprint in New Jersey...

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a...

Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)

STOCKHOLM, June 26, 2026 /PRNewswire/ --The FDA has requested additional data related to chemistry, manufacturing, and controls (CMC) and contract manufacturing facilities; no clinical...

Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)

STOCKHOLM, June 26, 2026 /PRNewswire/ --The FDA has requested additional data related to chemistry, manufacturing, and controls (CMC) and contract manufacturing facilities; no clinical...

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including...

Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at...

Breast cancer vaccine presentation includes final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participantsOvarian...

Jocelyn Freimuth and Camino Compass to Lead First-Ever Qualified Evaluator Workshop at Compounding360 Studio Sessions

Hosted free by Pharmacy Stars on June 25, eight Camino Compass faculty, led by Principal Faculty Jocelyn Freimuth, PharmD, MBA, BCSCP, will put 64...

Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026

SHANGHAI, June 14, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces poster...

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The results are being presented today in a late-breaking session at the European Hematology Association (EHA) 2026 Congress (Abstract #LB5006).

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Media Release

COPENHAGEN, Denmark; June 13, 2026

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInfusion

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers